Literature DB >> 8742125

Role of growth hormone and sex steroids in achieving and maintaining normal bone mass.

S J Holmes1, S M Shalet.   

Abstract

It is now established that adults with growth hormone (GH) deficiency, of childhood or adult onset, have reduced bone mass. GH deficiency is believed to interfere with acquisition of bone mass, although an alternative mechanism is required to explain the reduction in bone mass present in adults who acquire GH deficiency after peak bone mass has been achieved. GH replacement increases bone turnover and may increase bone mass in the longer term, although short-term studies show a decrease in bone mass which can be explained by an increase in bone resorption before new bone formation occurs. Abnormalities of GH secretion have also been implicated in the development of osteoporosis, but the effect of GH treatment on bone mass in such patients is disappointing. Sex steroids have an important role to play in the acquisition of bone mass, and reduced sex steroid levels during adolescence have a deleterious effect on bone mass. The importance of sex steroids in the maintenance of bone mass is illustrated by the development of osteopenia in men and women with hypogonadism, and by the preservation of bone mass by restoration of normal endogenous sex steroid levels, or by treatment with exogenous sex steroid. Sex steroids also influence circulating levels of GH and insulin-like growth factor-1, and the inter-action between these hormones is likely to be important in the acquisition and maintenance of normal bone mass.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8742125     DOI: 10.1159/000184765

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  12 in total

1.  Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.

Authors:  Subburaman Mohan; Charmaine Richman; Rongqing Guo; Yousef Amaar; Leah Rea Donahue; Jon Wergedal; David J Baylink
Journal:  Endocrinology       Date:  2003-03       Impact factor: 4.736

2.  Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover.

Authors:  A Gürlek; O Gedik
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

3.  Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns?

Authors:  W K Cho; M B Ahn; J-W Lee; N-G Chung; M H Jung; B Cho; B-K Suh
Journal:  Bone Marrow Transplant       Date:  2016-08-01       Impact factor: 5.483

Review 4.  Physical activity in the prevention and amelioration of osteoporosis in women : interaction of mechanical, hormonal and dietary factors.

Authors:  Katarina T Borer
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

5.  Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study.

Authors:  Adrian G Ruetsche; Renato Kneubuehl; Martin H Birkhaeuser; Kurt Lippuner
Journal:  Osteoporos Int       Date:  2004-10-16       Impact factor: 4.507

6.  Relationships between finger-length ratios, ghrelin, leptin, IGF axis, and sex steroids in young male and female swimmers.

Authors:  T Jürimäe; M Voracek; J Jürimäe; E Lätt; K Haljaste; M Saar; P Purge
Journal:  Eur J Appl Physiol       Date:  2008-06-27       Impact factor: 3.078

7.  A curious case of stress fracture in a transsexual athlete.

Authors:  Tom Richardson; Michael Grant; Prakash Chandran
Journal:  BMJ Case Rep       Date:  2016-03-31

Review 8.  Effects of GH/IGF axis on bone and cartilage.

Authors:  Manisha Dixit; Sher Bahadur Poudel; Shoshana Yakar
Journal:  Mol Cell Endocrinol       Date:  2020-10-14       Impact factor: 4.102

9.  Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist.

Authors:  Sandra B Alessandri; Francisco de A Pereira; Rosângela A Villela; Sonir R R Antonini; Paula C L Elias; Carlos E Martinelli; Margaret de Castro; Ayrton C Moreira; Francisco J A de Paula
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 10.  Sarcopenia during COVID-19 lockdown restrictions: long-term health effects of short-term muscle loss.

Authors:  Richard Kirwan; Deaglan McCullough; Tom Butler; Fatima Perez de Heredia; Ian G Davies; Claire Stewart
Journal:  Geroscience       Date:  2020-10-01       Impact factor: 7.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.